Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Delta-8-tetrahydrocannabinol (delta-8 THC) is a psychoactive cannabinoid found in the Cannabis sativa plant. It is an isomer of delta-9-tetrahydrocannabinol (delta-9 THC), the primary psychoactive component of cannabis. Delta-8 THC occurs naturally in very low concentrations and is typically produced by chemical conversion from hemp-derived cannabidiol (CBD). Its mechanism of action involves binding to cannabinoid receptor type 1 (CB1) and cannabinoid receptor type 2 (CB2) in the endocannabinoid system, resulting in psychoactive effects similar to but milder than those produced by delta-9 THC. Delta-8 THC has been used for effects such as pain reduction, sleep support, increased relaxation, and improved appetite[1][3][4][5][6]. The compound gained popularity after changes in U.S. law allowed for hemp-derived cannabinoids to be marketed more widely.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on delta-8-tetrahydrocannabinol.